Humoral Response of Buffaloes to a Recombinant Vaccine against Botulism Serotypes C and D

Otaka, Denis Y.; Barbosa, José Diomedes; Moreira, Clóvis; Ferreira, Marcos Roberto Alves; Cunha, C. E.; Brito, Antônio R S; Donassolo, Rafael Amaral; Moreira, Ângela Nunes; Conceição, Fabrı́cio R.; Salvarani, Felipe Masiero

doi:10.3390/toxins9100297

Cited by 13 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animals that were immunized with 200 µg per dose, produced up to 8 and 10 IU/mL of anti-BoNTs C and D, respectively, with 100% (8/8) seroconversion rate at day 56 post-vaccination. Furthermore, Otaka et al [ 13 ] used the same strategy and dose to immunize buffaloes, obtaining 6.1 and 6.2 IU/mL of antitoxins against BoNTs C and D, respectively, in agreement with the requirements of MAPA’s normative instruction n. 23.…”

Section: Discussionmentioning

confidence: 72%

“…Neutralizing antibody titers were shown to be dependent on the dose of H C BoNT/C and D used in the vaccine. It was possible to establish a linear positive correlation between antigen amount per vaccine dose and neutralizing antibody titers for both BoNT serotypes C and D (r C 2 = 0.823 and r D 2 = 0.866) similar to correlation observed in buffaloes vaccinated with same recombinant vaccine (r C 2 = 0.897 and r D 2 = 0.920) [ 13 ]. These analyses show that at least 167 µg of H C BoNT/C and 108 µg of H C BoNT/D are required to induce a protective immune response in cattle, surpassing the minimum required by MAPA; likewise, 180 µg of H C BoNT/C and 105 µg of H C BoNT/D are necessary to achieve the same standards when vaccinating buffaloes [ 13 ].…”

Section: Discussionmentioning

confidence: 81%

“…The fermentation procedure also presents high biological risk both to workers and to the environment as BoNTs are the most potent toxins known [ 2 ]. As an alternative to toxoids, the use of recombinant vaccines comprising the C-terminal portion of BoNTs serotypes C and D heavy-chain (H C BoNT/C and D) has been considered safe and effective in many animal species [ 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle

Moreira

Ferreira

Cunha

et al. 2018

Toxins

Self Cite

View full text Add to dashboard Cite

Botulism is a potentially fatal intoxication caused by botulinum neurotoxins (BoNTs) produced mainly by Clostridium botulinum. Vaccination against BoNT serotypes C and D is the main procedure to control cattle botulism. Current vaccines contain formaldehyde-inactivated native BoNTs, which have a time-consuming production process and pose safety risks. The development of non-toxic recombinant vaccines has helped to overcome these limitations. This study aims to evaluate the humoral immune response generated by cattle immunized with non-purified recombinant fragments of BoNTs C and D. Cattle were vaccinated in a two-dose scheme with 100, 200 and 400 µg of each antigen, with serum sampling on days 0, 56, 120, and 180 after vaccination. Animals who received either 200 or 400 μg of both antigens induced titers higher than the minimum required by the Brazilian ministry of Agriculture, Livestock and Food Supply and achieved 100% (8/8) seroconversion rate. Animals vaccinated with commercial toxoid vaccine had only a 75% (6/8) seroconversion rate for both toxins. Animals that received doses containing 400 µg of recombinant protein were the only ones to maintain titers above the required level up until day 120 post-vaccination, and to achieve 100% (8/8) seroconversion for both toxins. In conclusion, 400 µg the recombinant Escherichia coli cell lysates supernatant was demonstrated to be an affordable means of producing an effective and safe botulism vaccine for cattle.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 81%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle

Moreira

Ferreira

Cunha

et al. 2018

Toxins

Self Cite

View full text Add to dashboard Cite

show abstract

“…On day 56 after the first vaccine dose, moment in which the vaccine efficiency is evaluated, through the potency test in the target species according to the literature (Moreira et al 2016, 2018, Otaka et al 2017, blood samples were collected by jugular venipuncture. After clot formation, centrifugation was performed at 3000g for 5 minutes to obtain serum, which was stored at -20°C until further use.…”

Section: Methodsmentioning

confidence: 99%

Clostridium perfringens α and β recombinant toxoids in equine immunization

et al. 2020

View full text Add to dashboard Cite

Clostridium perfringens is considered one of the main causative agents of superacute enterocolitis, usually fatal in the equine species, due to the action of the β toxin, and is responsible for causing severe myonecrosis, by the action of the α toxin. The great importance of this agent in the equine economy is due to high mortality and lack of vaccines, which are the main form of prevention, which guarantee the immunization of this animal species. The aim of this study was to evaluate three different concentrations (100, 200 and 400μg) of C. perfringens α and β recombinant toxoids in equine immunization and to compare with a group vaccinated with a commercial toxoid. The commercial vaccine was not able to stimulate an immune response and the recombinant vaccine was able to induce satisfactory humoral immune response in vaccinated horses, proving to be an alternative prophylactic for C. perfringens infection.

show abstract

“…Nicola Bak, Dorothea Sesardic, and their team from the United Kingdom, reported on the application of SiMa cells for cell-based neutralization test for BoNT/A and BoNT/E [14]. On the vaccine development side, Robert P. Webb, Theresa J. Smith, and their team from USAMRIID, reported on the production of non-toxic holoproteins and recombinant BoNT toxin domain subunits as vaccine candidates against multiple serotypes [15], Denis Y. Otaka, Felipe M. Salvarani, and their team from Brazil, reported on the humoral response of buffalos to a recombinant vaccine against BoNT/C and D [16]. Finally, Hyun Jung Chang, Bo Young Hong, Jeong-Yi Kwon, and their teams from South Korea, report results from a clinical trial on the efficacy and safety of Botulax for the treatment of dynamic equinus foot deformity in children with cerebral palsy [17].…”

mentioning

confidence: 99%